Zotiraciclib

DB16656InvestigationalSmall molecule

Zotiraciclib is under investigation in clinical trial NCT02942264 (Zotiraciclib (TG02) Plus Dose-dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in...

Mechanism: Pharmacologically active on Receptor-type tyrosine-protein kinase FLT3, Cyclin-dependent kinase 2, and Cyclin-dependent kinase 1
Curator reviewed
Formula / weight: C₂₃H₂₄N₄O · 372.472 g/mol (avg)
Code names: EX 45 · SB-1317 free base · TG-02

Resolves to

Compound

UNII40D08182TTCAS1204918-72-8ChEMBLCHEMBL1944698

Structure

InChIKeyVXBAJLGYBMTJCY-NSCUHMNNSA-NSMILESCN1C\C=C\CCOC2=CC(=CC=C2)C2=CC=NC(NC3=CC=CC(C1)=C3)=N2

Targets

P36888FLT3P24941CDK2P06493CDK1P50613CDK7O60674JAK2P50750CDK9P06241FYNP06239LCK

What you can answer from here — as of September 12, 2026

8Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

20+ReferencesStructured and connected to the statements they support

Which drugs share a target with Zotiraciclib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account